Ligand Pharmaceuticals Incorporated (LGND)

Total asset turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 167,133 152,422 133,478 118,313 131,314 153,595 186,815 217,868 219,582 241,673 240,420 267,676 277,133 274,650 251,663 208,408 186,419 143,432 126,392 109,959
Total assets US$ in thousands 941,774 954,866 866,405 913,869 833,064 769,210 758,105 811,076 762,668 1,051 1,076,290 1,105,180 1,301,380 1,273,660 1,256,280 1,295,120 1,362,280 1,247,450 1,242,940 1,185,920
Total asset turnover 0.18 0.16 0.15 0.13 0.16 0.20 0.25 0.27 0.29 229.95 0.22 0.24 0.21 0.22 0.20 0.16 0.14 0.11 0.10 0.09

December 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $167,133K ÷ $941,774K
= 0.18

Ligand Pharmaceuticals Incorporated's total asset turnover ratio has shown fluctuating trends over the past few years. The ratio increased from 0.09 on March 31, 2020, to a peak of 0.29 on December 31, 2022. However, after reaching its highest point, it decreased to 0.18 by December 31, 2024.

Overall, the company's total asset turnover ratio indicates how efficiently it is utilizing its assets to generate revenue. It is essential to monitor this ratio closely to assess the effectiveness of Ligand Pharmaceuticals in generating sales relative to its total assets.